Market Report covers Colon Cancer - Pipeline Review, H1 2016

Colon Cancer - Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Colon Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Colon Cancer, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

To access full report with TOC, please visit ​Colon Cancer - Pipeline Review, H1 2016.

Scope

- The report provides a snapshot of the global therapeutic landscape of Colon Cancer
- The report reviews pipeline therapeutics for Colon Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Colon Cancer

Reasons to buy

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

ACF Pharmaceuticals, LLC Adgero Biopharmaceuticals, Inc. Aduro BioTech, Inc. Advanced Proteome Therapeutics Corporation Advenchen Laboratories, LLC Agenus, Inc. AGV Discovery, SAS AIMM Therapeutics B.V. Ambrx, Inc. Anavex Life Sciences Corp. AndroScience Corporation Aphios Corporation Aposense Ltd. Aptose Biosciences Inc. Asana BioSciences, LLC AstraZeneca Plc Aurigene Discovery Technologies Limited BCN Biosciences L.L.C. Bio-Path Holdings, Inc. Biogazelle Bioncotech Therapeutics S.L. Blirt S.A. Boehringer Ingelheim GmbH Can-Fite BioPharma Ltd. Celprogen, Inc. Celyad SA Chiome Bioscience, Inc. Critical Outcome Technologies Inc. Cyclacel Pharmaceuticals, Inc. CytomX Therapeutics, Inc. Cytune Pharma SAS CZ BioMed Corp DEKK-TEC, Inc. Digna Biotech, S.L. Eli Lilly and Company EntreChem, S.L. EnzymeBioSystems F. Hoffmann-La Roche Ltd. GlycaNova Norway AS Halozyme Therapeutics, Inc. Heat Biologics, Inc. Helix BioPharma Corp. Histogen, Inc. Horizon Pharma Plc Huperion Sarl Idera Pharmaceuticals, Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###